bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S1 from Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial
Authors: Mauge Laetitia , Mejean Arnaud , Fournier Laure , Pereira Helena , Etienne-Grimaldi Marie-Christine , Levionnois Emeline , Caty Armelle , Abadie-Lacourtoisie Sophie , Culine Stéphane , Le Moulec Sylvestre , Linassier Claude , Théodore Christine , Ravaud Alain , Albiges Laurence , Grine Abel , Tartour Eric , Milano Gérard , Gille Anne-Sophie , Verkarre Virginie , Helley Dominique , Oudard Stéphane
Published: April 2023

PREINSUT study group
Supplement Table S5 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplement Table S5. List of differential lipids and their classification.
Supplementary Tables S3, S4, S6, S7, S8 from Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Authors: Mohan Dipika R. , Lerario Antonio Marcondes , Else Tobias , Mukherjee Bhramar , Almeida Madson Q. , Vinco Michelle , Rege Juilee , Mariani Beatriz M. P. , Zerbini Maria Claudia N. , Mendonca Berenice B. , Latronico Ana Claudia , Marie Suely K. N. , Rainey William E. , Giordano Thomas J. , Fragoso Maria Candida B. V. , Hammer Gary D.
Published: April 2023

This compiled PDF includes Supplementary Tables S3, S4, S6, S7, and S8, as follows: Supp. Table S3. G0S2 hypermethylation predicts CIMP-high. Supp. Table S4. Clinical characteristics of FMUSP+UM ACC and ACA Cohorts. Supp. Table S6. EpiTect accurately measures binary G0S2 methylation status. Supp. Table S7. Hypermethylation and silencing of G0S2 is heterogeneous in recurrent, metastatic, and non-treatment naive carcinomas. Supp. Table S8. BUB1B-PINK1 can predict any history of metastasis in patients with G0S2 Unmethylated ACC.
Supplementary Table S9 from Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Authors: Mohan Dipika R. , Lerario Antonio Marcondes , Else Tobias , Mukherjee Bhramar , Almeida Madson Q. , Vinco Michelle , Rege Juilee , Mariani Beatriz M. P. , Zerbini Maria Claudia N. , Mendonca Berenice B. , Latronico Ana Claudia , Marie Suely K. N. , Rainey William E. , Giordano Thomas J. , Fragoso Maria Candida B. V. , Hammer Gary D.
Published: April 2023

Complete clinical and molecular data of all samples used in this study.
Supplementary Table S5 from Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Authors: Mohan Dipika R. , Lerario Antonio Marcondes , Else Tobias , Mukherjee Bhramar , Almeida Madson Q. , Vinco Michelle , Rege Juilee , Mariani Beatriz M. P. , Zerbini Maria Claudia N. , Mendonca Berenice B. , Latronico Ana Claudia , Marie Suely K. N. , Rainey William E. , Giordano Thomas J. , Fragoso Maria Candida B. V. , Hammer Gary D.
Published: April 2023

Results of G0S2 targeted bisulfite sequencing.
Figure S3 from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Authors: Hariri Lida P. , Adams David C. , Applegate Matthew B. , Miller Alyssa J. , Roop Benjamin W. , Villiger Martin , Bouma Brett E. , Suter Melissa J.
Published: April 2023

Figure S3 from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Supplementary Table S2 from Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Authors: Mohan Dipika R. , Lerario Antonio Marcondes , Else Tobias , Mukherjee Bhramar , Almeida Madson Q. , Vinco Michelle , Rege Juilee , Mariani Beatriz M. P. , Zerbini Maria Claudia N. , Mendonca Berenice B. , Latronico Ana Claudia , Marie Suely K. N. , Rainey William E. , Giordano Thomas J. , Fragoso Maria Candida B. V. , Hammer Gary D.
Published: April 2023

Results of DMRcate analysis on ACC-TCGA non-CIMP-high v. CIMP-high.
Figure S1 from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Authors: Hariri Lida P. , Adams David C. , Applegate Matthew B. , Miller Alyssa J. , Roop Benjamin W. , Villiger Martin , Bouma Brett E. , Suter Melissa J.
Published: April 2023

Figure S1 from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Supplementary Table S1 from Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Authors: Mohan Dipika R. , Lerario Antonio Marcondes , Else Tobias , Mukherjee Bhramar , Almeida Madson Q. , Vinco Michelle , Rege Juilee , Mariani Beatriz M. P. , Zerbini Maria Claudia N. , Mendonca Berenice B. , Latronico Ana Claudia , Marie Suely K. N. , Rainey William E. , Giordano Thomas J. , Fragoso Maria Candida B. V. , Hammer Gary D.
Published: April 2023

Results of differentially expressed genes analysis on ACC-TCGA CIMP-high v. non-CIMP-high and results of gene ontology analysis on ACC-TCGA CIMP-high v. non-CIMP-high.
Supplementary Figures S1-S7 from Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Authors: Mohan Dipika R. , Lerario Antonio Marcondes , Else Tobias , Mukherjee Bhramar , Almeida Madson Q. , Vinco Michelle , Rege Juilee , Mariani Beatriz M. P. , Zerbini Maria Claudia N. , Mendonca Berenice B. , Latronico Ana Claudia , Marie Suely K. N. , Rainey William E. , Giordano Thomas J. , Fragoso Maria Candida B. V. , Hammer Gary D.
Published: April 2023

This compiled PDF includes Supplementary Figures S1-S7 and figure legends, as follows: Supp. Fig. S1. ACC-TCGA patients with CIMP-low or CIMP-intermediate tumor status exhibit indistinguishable disease kinetics, while patients with CIMP-high tumor status have deadly disease course. Supp. Fig. S2. Schematic of the G0S2 locus. Supp. Fig. S3. G0S2 is highly expressed in the human adrenal gland. Supp Fig. S4. Unsupervised hierarchical clustering of G0S2 CpG island methylaiton enables identification of CIMP-high ACC. Supp. Fig. S5. G0S2 hypermethylation is exclusive to malignant adrenocortical tumors and can be reliably measured by EpiTect. Supp. Fig. S6. G0S2 expression/methylation ROC curve. Supp. Fig. S7. BUB1B-PINK1 score can predict metastasis in G0S2 Unmethylated ACC.
Supplemental Table 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Authors: DuBois Steven G. , Mosse Yael P. , Fox Elizabeth , Kudgus Rachel A. , Reid Joel M. , McGovern Renee , Groshen Susan , Bagatell Rochelle , Maris John M. , Twist Clare J. , Goldsmith Kelly , Granger M. Meaghan , Weiss Brian , Park Julie R. , Macy Margaret E. , Cohn Susan L. , Yanik Greg , Wagner Lars M. , Hawkins Randall , Courtier Jesse , Lai Hollie , Goodarzian Fariba , Shimada Hiroyuki , Boucher Najee , Czarnecki Scarlett , Luo Chunqiao , Tsao-Wei Denice , Matthay Katherine K. , Marachelian Araz
Published: April 2023

Supplemental Table 2
Supplemental Table 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Authors: DuBois Steven G. , Mosse Yael P. , Fox Elizabeth , Kudgus Rachel A. , Reid Joel M. , McGovern Renee , Groshen Susan , Bagatell Rochelle , Maris John M. , Twist Clare J. , Goldsmith Kelly , Granger M. Meaghan , Weiss Brian , Park Julie R. , Macy Margaret E. , Cohn Susan L. , Yanik Greg , Wagner Lars M. , Hawkins Randall , Courtier Jesse , Lai Hollie , Goodarzian Fariba , Shimada Hiroyuki , Boucher Najee , Czarnecki Scarlett , Luo Chunqiao , Tsao-Wei Denice , Matthay Katherine K. , Marachelian Araz
Published: April 2023

Supplemental Table 1
Supplemental Figure Legends from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Authors: DuBois Steven G. , Mosse Yael P. , Fox Elizabeth , Kudgus Rachel A. , Reid Joel M. , McGovern Renee , Groshen Susan , Bagatell Rochelle , Maris John M. , Twist Clare J. , Goldsmith Kelly , Granger M. Meaghan , Weiss Brian , Park Julie R. , Macy Margaret E. , Cohn Susan L. , Yanik Greg , Wagner Lars M. , Hawkins Randall , Courtier Jesse , Lai Hollie , Goodarzian Fariba , Shimada Hiroyuki , Boucher Najee , Czarnecki Scarlett , Luo Chunqiao , Tsao-Wei Denice , Matthay Katherine K. , Marachelian Araz
Published: April 2023

Supplemental Figure Legends
Table S4 from Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Authors: Noh Ka-Won , Sohn Insuk , Song Ji-Young , Shin Hyun-Tae , Kim Yu-Jin , Jung Kyungsoo , Sung Minjung , Kim Mingi , An Sungbin , Han Joungho , Lee Se-Hoon , Lee Mi-Sook , Choi Yoon-La
Published: April 2023

Clinical characteristics in ALK-rearranged NSCLC based on integrin β3 immunohistochemistry score
Supplemental Figure 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Authors: DuBois Steven G. , Mosse Yael P. , Fox Elizabeth , Kudgus Rachel A. , Reid Joel M. , McGovern Renee , Groshen Susan , Bagatell Rochelle , Maris John M. , Twist Clare J. , Goldsmith Kelly , Granger M. Meaghan , Weiss Brian , Park Julie R. , Macy Margaret E. , Cohn Susan L. , Yanik Greg , Wagner Lars M. , Hawkins Randall , Courtier Jesse , Lai Hollie , Goodarzian Fariba , Shimada Hiroyuki , Boucher Najee , Czarnecki Scarlett , Luo Chunqiao , Tsao-Wei Denice , Matthay Katherine K. , Marachelian Araz
Published: April 2023

Supplemental Figure 2
Supplemental Figure 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Authors: DuBois Steven G. , Mosse Yael P. , Fox Elizabeth , Kudgus Rachel A. , Reid Joel M. , McGovern Renee , Groshen Susan , Bagatell Rochelle , Maris John M. , Twist Clare J. , Goldsmith Kelly , Granger M. Meaghan , Weiss Brian , Park Julie R. , Macy Margaret E. , Cohn Susan L. , Yanik Greg , Wagner Lars M. , Hawkins Randall , Courtier Jesse , Lai Hollie , Goodarzian Fariba , Shimada Hiroyuki , Boucher Najee , Czarnecki Scarlett , Luo Chunqiao , Tsao-Wei Denice , Matthay Katherine K. , Marachelian Araz
Published: April 2023

Supplemental Figure 1
Table S1 from Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Authors: Noh Ka-Won , Sohn Insuk , Song Ji-Young , Shin Hyun-Tae , Kim Yu-Jin , Jung Kyungsoo , Sung Minjung , Kim Mingi , An Sungbin , Han Joungho , Lee Se-Hoon , Lee Mi-Sook , Choi Yoon-La
Published: April 2023

Clinical characteristics of ALK-rearranged and ALK-negative NSCLC patients
Figure S1 from Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Authors: Noh Ka-Won , Sohn Insuk , Song Ji-Young , Shin Hyun-Tae , Kim Yu-Jin , Jung Kyungsoo , Sung Minjung , Kim Mingi , An Sungbin , Han Joungho , Lee Se-Hoon , Lee Mi-Sook , Choi Yoon-La
Published: April 2023

ALK and integrin β3 show strong correlation in expression in ALK-rearranged NSCLC patient cases and in vitro
Table S1 from The Sentinel Margin: Intraoperative Ex Vivo Specimen Mapping Using Relative Fluorescence Intensity
Authors: van Keulen Stan , Nishio Naoki , Birkeland Andrew , Fakurnejad Shayan , Martin Brock , Forouzanfar Tim , Cunanan Kristen , Colevas A. Dimitrios , S. van den Berg Nynke , Rosenthal Eben
Published: April 2023

(*) Excluded due to bone containing specimen. DOI: depth of invasion; hrs: hours; mg: milligram; mm: millimeter; pTN-stage: pathological Tumor, Node-stage
Figure S1 from The Sentinel Margin: Intraoperative Ex Vivo Specimen Mapping Using Relative Fluorescence Intensity
Authors: van Keulen Stan , Nishio Naoki , Birkeland Andrew , Fakurnejad Shayan , Martin Brock , Forouzanfar Tim , Cunanan Kristen , Colevas A. Dimitrios , S. van den Berg Nynke , Rosenthal Eben
Published: April 2023

Supplemental Figure 1 Annotation of suspicious area by suture. (a + b) Bright field (a) and corresponding fluorescence image (b) of the specimen's deep margin after maxillectomy. White solid line indicates peak intensity area in a. and b. White dotted line delineates the infiltrated left concha inferior (nasal cavity). (d) Isolated fluorescence intensity-peak area where suture was placed (with color bar). (c) Hematoxylin & eosin slide of suture marked area. Black solid line delineates tumor from healthy tissue.
Suppl. Figure 6 from Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance
Authors: Wartenberg Martin , Cibin Silvia , Zlobec Inti , Vassella Erik , Eppenberger-Castori Serenella , Terracciano Luigi , Eichmann Micha David , Worni Mathias , Gloor Beat , Perren Aurel , Karamitopoulou Eva
Published: April 2023

MMR-proteins
Supplementary Methods, Supplementary Tables 1-3, Supplementary Figure 1 from Exosome-Based Detection of EGFR T790M in Plasma from Non–Small Cell Lung Cancer Patients
Authors: Castellanos-Rizaldos Elena , Grimm Dominik G. , Tadigotla Vasisht , Hurley James , Healy John , Neal Patricia L. , Sher Mia , Venkatesan Raajdeep , Karlovich Chris , Raponi Mitch , Krug Anne , Noerholm Mikkel , Tannous Jihane , Tannous Bakhos A. , Raez Luis E. , Skog Johan K.
Published: April 2023

Supplementary Table 1. Clinical characteristics of patients included in the study (T790M positive/negative and the different pools of plasma from healthy donors); Supplementary Table 2. Mutant admixtures used as part of the analytical validation. These samples were run using three technical replicates; Supplementary Table 3. Analytical validation. Supplementary Table 4. Summary of patient demographics and T790M results for the validation cohort; Supplementary Figure 1. Patient histology for T790M positive and negative patients (A) and disease distribution by stage (B) for all the clinical samples.
Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Authors: Pasch Cheri A. , Favreau Peter F. , Yueh Alexander E. , Babiarz Christopher P. , Gillette Amani A. , Sharick Joe T. , Karim Mohammad Rezaul , Nickel Kwangok P. , DeZeeuw Alyssa K. , Sprackling Carley M. , Emmerich Philip B. , DeStefanis Rebecca A. , Pitera Rosabella T. , Payne Susan N. , Korkos Demetra P. , Clipson Linda , Walsh Christine M. , Miller Devon , Carchman Evie H. , Burkard Mark E. , Lemmon Kayla K. , Matkowskyj Kristina A. , Newton Michael A. , Ong Irene M. , Bassetti Michael F. , Kimple Randall J. , Skala Melissa C. , Deming Dustin A.
Published: April 2023

Detailed characteristics of CRC PDOCS.
Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Authors: Pasch Cheri A. , Favreau Peter F. , Yueh Alexander E. , Babiarz Christopher P. , Gillette Amani A. , Sharick Joe T. , Karim Mohammad Rezaul , Nickel Kwangok P. , DeZeeuw Alyssa K. , Sprackling Carley M. , Emmerich Philip B. , DeStefanis Rebecca A. , Pitera Rosabella T. , Payne Susan N. , Korkos Demetra P. , Clipson Linda , Walsh Christine M. , Miller Devon , Carchman Evie H. , Burkard Mark E. , Lemmon Kayla K. , Matkowskyj Kristina A. , Newton Michael A. , Ong Irene M. , Bassetti Michael F. , Kimple Randall J. , Skala Melissa C. , Deming Dustin A.
Published: April 2023

Stock culture and feeding media.
Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Authors: Pasch Cheri A. , Favreau Peter F. , Yueh Alexander E. , Babiarz Christopher P. , Gillette Amani A. , Sharick Joe T. , Karim Mohammad Rezaul , Nickel Kwangok P. , DeZeeuw Alyssa K. , Sprackling Carley M. , Emmerich Philip B. , DeStefanis Rebecca A. , Pitera Rosabella T. , Payne Susan N. , Korkos Demetra P. , Clipson Linda , Walsh Christine M. , Miller Devon , Carchman Evie H. , Burkard Mark E. , Lemmon Kayla K. , Matkowskyj Kristina A. , Newton Michael A. , Ong Irene M. , Bassetti Michael F. , Kimple Randall J. , Skala Melissa C. , Deming Dustin A.
Published: April 2023

Success rates for growing human cancers in spheroid culture
Figure S6 from [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Authors: Verwer Eline E. , Kavanagh Taylor R. , Mischler William J. , Feng You , Takahashi Kazue , Wang Shuyan , Shoup Timothy M. , Neelamegam Ramesh , Yang Jing , Guehl Nicolas J. , Ran Chongzhao , Massefski Walter , Cui Ye , El-Chemaly Souheil , Sadow Peter M. , Oldham William M. , Kijewski Marie F. , El Fakhri Georges , Normandin Marc D. , Priolo Carmen
Published: April 2023

Increased mitochondrial acetate oxidation induced by treatment with rapamycin.
Figure S5 from [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Authors: Verwer Eline E. , Kavanagh Taylor R. , Mischler William J. , Feng You , Takahashi Kazue , Wang Shuyan , Shoup Timothy M. , Neelamegam Ramesh , Yang Jing , Guehl Nicolas J. , Ran Chongzhao , Massefski Walter , Cui Ye , El-Chemaly Souheil , Sadow Peter M. , Oldham William M. , Kijewski Marie F. , El Fakhri Georges , Normandin Marc D. , Priolo Carmen
Published: April 2023

[18F]FACE-PET of TSC2-deficient tumors after 48-hr exposure to rapamycin or vehicle control.
Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Authors: Pasch Cheri A. , Favreau Peter F. , Yueh Alexander E. , Babiarz Christopher P. , Gillette Amani A. , Sharick Joe T. , Karim Mohammad Rezaul , Nickel Kwangok P. , DeZeeuw Alyssa K. , Sprackling Carley M. , Emmerich Philip B. , DeStefanis Rebecca A. , Pitera Rosabella T. , Payne Susan N. , Korkos Demetra P. , Clipson Linda , Walsh Christine M. , Miller Devon , Carchman Evie H. , Burkard Mark E. , Lemmon Kayla K. , Matkowskyj Kristina A. , Newton Michael A. , Ong Irene M. , Bassetti Michael F. , Kimple Randall J. , Skala Melissa C. , Deming Dustin A.
Published: April 2023

Individual replicates for data shown in Figure 5E.
Figure S4 from [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Authors: Verwer Eline E. , Kavanagh Taylor R. , Mischler William J. , Feng You , Takahashi Kazue , Wang Shuyan , Shoup Timothy M. , Neelamegam Ramesh , Yang Jing , Guehl Nicolas J. , Ran Chongzhao , Massefski Walter , Cui Ye , El-Chemaly Souheil , Sadow Peter M. , Oldham William M. , Kijewski Marie F. , El Fakhri Georges , Normandin Marc D. , Priolo Carmen
Published: April 2023

[18F]FACE-PET of TSC2-deficient tumors after 72-hr exposure to vehicle control (a representative mouse).
Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Authors: Pasch Cheri A. , Favreau Peter F. , Yueh Alexander E. , Babiarz Christopher P. , Gillette Amani A. , Sharick Joe T. , Karim Mohammad Rezaul , Nickel Kwangok P. , DeZeeuw Alyssa K. , Sprackling Carley M. , Emmerich Philip B. , DeStefanis Rebecca A. , Pitera Rosabella T. , Payne Susan N. , Korkos Demetra P. , Clipson Linda , Walsh Christine M. , Miller Devon , Carchman Evie H. , Burkard Mark E. , Lemmon Kayla K. , Matkowskyj Kristina A. , Newton Michael A. , Ong Irene M. , Bassetti Michael F. , Kimple Randall J. , Skala Melissa C. , Deming Dustin A.
Published: April 2023

Dot plots corresponding to population distribution curves and graphs of individual replicates for bar graphs in Figure 4.
Table S3 from Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis
Authors: Noda Masaru , Okayama Hirokazu , Tachibana Kazunoshin , Sakamoto Wataru , Saito Katsuharu , Thar Min Aung Kyi , Ashizawa Mai , Nakajima Takahiro , Aoto Keita , Momma Tomoyuki , Katakura Kyoko , Ohki Shinji , Kono Koji
Published: April 2023

Table S3
Figure S3 from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Authors: Sharma Priyanka , López-Tarruella Sara , García-Saenz José Angel , Khan Qamar J. , Gómez Henry L. , Prat Aleix , Moreno Fernando , Jerez-Gilarranz Yolanda , Barnadas Agustí , Picornell Antoni C. , Monte-Millán María del , González-Rivera Milagros , Massarrah Tatiana , Pelaez-Lorenzo Beatriz , Palomero María Isabel , González del Val Ricardo , Cortés Javier , Fuentes-Rivera Hugo , Morales Denisse Bretel , Márquez-Rodas Iván , Perou Charles M. , Lehn Carolyn , Wang Yen Y. , Klemp Jennifer R. , Mammen Joshua V. , Wagner Jamie L. , Amin Amanda L. , O’Dea Anne P. , Heldstab Jaimie , Jensen Roy A. , Kimler Bruce F. , Godwin Andrew K. , Martín Miguel
Published: April 2023

Recurrence-free survival and overall survival by adjuvant chemotherapy use in RCB II/III patients
Supplementary data from Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis
Authors: Noda Masaru , Okayama Hirokazu , Tachibana Kazunoshin , Sakamoto Wataru , Saito Katsuharu , Thar Min Aung Kyi , Ashizawa Mai , Nakajima Takahiro , Aoto Keita , Momma Tomoyuki , Katakura Kyoko , Ohki Shinji , Kono Koji
Published: April 2023

Figure S1-S13, Table S4-S12
Figure S2 from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Authors: Sharma Priyanka , López-Tarruella Sara , García-Saenz José Angel , Khan Qamar J. , Gómez Henry L. , Prat Aleix , Moreno Fernando , Jerez-Gilarranz Yolanda , Barnadas Agustí , Picornell Antoni C. , Monte-Millán María del , González-Rivera Milagros , Massarrah Tatiana , Pelaez-Lorenzo Beatriz , Palomero María Isabel , González del Val Ricardo , Cortés Javier , Fuentes-Rivera Hugo , Morales Denisse Bretel , Márquez-Rodas Iván , Perou Charles M. , Lehn Carolyn , Wang Yen Y. , Klemp Jennifer R. , Mammen Joshua V. , Wagner Jamie L. , Amin Amanda L. , O’Dea Anne P. , Heldstab Jaimie , Jensen Roy A. , Kimler Bruce F. , Godwin Andrew K. , Martín Miguel
Published: April 2023

Recurrence-free survival and overall survival in the overall patient population
Table S6 from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

Analysis of Linear Model at Selected Thresholds
Supplementary Tables from Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth
Authors: Lamano Jonathan B. , Lamano Jason Balquidera , Li Yuping D. , DiDomenico Joseph D. , Choy Winward , Veliceasa Dorina , Oyon Daniel E. , Fakurnejad Shayan , Ampie Leonel , Kesavabhotla Kartik , Kaur Rajwant , Kaur Gurvinder , Biyashev Dauren , Unruh Dusten J. , Horbinski Craig M. , James C. David , Parsa Andrew T. , Bloch Orin
Published: April 2023

Supplementary Tables S1-S4.
Table S3 from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

Clinicopathologic Features by Treatment & Risk Group (margin negative)
Supplementary Figures from IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lenzen Alicia , Lauing Kristen L. , Qian Jun , Scholtens Denise M. , Gritsina Galina , Sun Xuebing , Liu Ye , Yu Fenglong , Gong Wenfeng , Liu Yong , Jiang Beibei , Tang Tristin , Patel Ricky , Platanias Leonidas C. , James C. David , Stupp Roger , Lukas Rimas V. , Binder David C. , Wainwright Derek A.
Published: April 2023

Supplementary figures and associated legends Supplementary Figure 1. In vitro GBM cell IDO1 metabolism with or without treatment of interferon-gamma (IFNï�§ï€©ï€ and/or IDO1 enzyme inhibitor, BGB-5777. Supplemental Figure 2. Mouse and human glioblastoma (GBM) cell IDO1 mRNA expression with or without IFNÎ³ treatment. Supplemental Figure 3. Monotherapeutic effects of BGB-5777 in subcutaneously-engrafted mouse cancer models. Supplemental Figure 4. Survival comparison of mice treated with BGB-5777, radiotherapy and either PD-1 mAb or PD-L1 mAb. Supplemental Figure 5. Cellular analysis of glioblastoma (GBM) at 3 weeks post-tumor cell engraftment and treated with trimodal therapy. Supplemental Figure 6. Metabolite analysis of mice with glioblastoma (GBM) at 3 weeks post-tumor cell engraftment and treated with BGB-5777 monotherapy.
Table S3 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

Clinicopathological features in patients with NSCLC (n = 27).
Figure S3 from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

Figure S3. Baseline Risks as a Function of Year of Diagnosis
Table S2 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

Clinicopathological features in patients with RCC (n = 29).
Legends for supplementry figures from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

Legends for supplementry figures.
Figure S9 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

Effector CD8+ T cells detected by CD44+CD62L-CD8+ T cells, PD-1+CD8+ T cells, and cytokine-producing CD8+ T cells in TILs from MC-38-L2 tumors.
S2 from Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model
Authors: Nguyen Ferro , Alferiev Ivan , Guan Peng , Guerrero David T. , Kolla Venkatadri , Moorthy Ganesh S. , Chorny Michael , Brodeur Garrett M.
Published: April 2023

Supp Figure S2 Figure S2. Ki-67 indices of tumor samples. A, Ki-67 staining of a CPT-11 retreated tumor showing abundant undifferentiated NB cells and a high (>30%) Ki-67 index. B, Ki-67 staining of a SN38-TOA NP retreated tumor showing ganglion-like NB cells and a very low (<1%) Ki-67 index.
Figure S7 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

In vivo tumor growth treated with anti-PD-1 and/or anti-PD-L2 mAb in immunocompetent mice.
Figure S4 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

Effector CD8+ T cells detected by CD44+CD62L-CD8+ T cells, PD-1+CD8+ T cells, and cytokine-producing CD8+ T cells in TILs from MC-38 tumors.
Supplementary Table S6 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Authors: Yan Yibing , Wongchenko Matthew J. , Robert Caroline , Larkin James , Ascierto Paolo A. , Dréno Brigitte , Maio Michele , Garbe Claus , Chapman Paul B. , Sosman Jeffrey A. , Shi Zhen , Koeppen Hartmut , Hsu Jessie J. , Chang Ilsung , Caro Ivor , Rooney Isabelle , McArthur Grant A. , Ribas Antoni
Published: April 2023

Supplementary Table S6 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Supplementary Table S5 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Authors: Yan Yibing , Wongchenko Matthew J. , Robert Caroline , Larkin James , Ascierto Paolo A. , Dréno Brigitte , Maio Michele , Garbe Claus , Chapman Paul B. , Sosman Jeffrey A. , Shi Zhen , Koeppen Hartmut , Hsu Jessie J. , Chang Ilsung , Caro Ivor , Rooney Isabelle , McArthur Grant A. , Ribas Antoni
Published: April 2023

Supplementary Table S5 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Figure S2 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

In vitro PD-L2 expression in MC38, CT26-NY-ESO-1, B16-F10, Renca, CMS5a and A20 treated with or without IFN-α, IFN-β, IFN-γ, TNF-α, IL-2, IL-4, TGF-β1 or GM-CSF.
Supplementary Table S4 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Authors: Yan Yibing , Wongchenko Matthew J. , Robert Caroline , Larkin James , Ascierto Paolo A. , Dréno Brigitte , Maio Michele , Garbe Claus , Chapman Paul B. , Sosman Jeffrey A. , Shi Zhen , Koeppen Hartmut , Hsu Jessie J. , Chang Ilsung , Caro Ivor , Rooney Isabelle , McArthur Grant A. , Ribas Antoni
Published: April 2023

Supplementary Table S4 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Figure S12 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

The relationship between CD274 or PDCD1LG2 expressions and survival in RCC and LUSC.
Figure S11 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

The scattergram and real number of pearson correlations between expression levels (RPKM) of immune-related genes and CD274 or PDCD1LG2 in BLCA, GC, HNSC, LUAD and LUSC.
Supplementary Table S2 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Authors: Yan Yibing , Wongchenko Matthew J. , Robert Caroline , Larkin James , Ascierto Paolo A. , Dréno Brigitte , Maio Michele , Garbe Claus , Chapman Paul B. , Sosman Jeffrey A. , Shi Zhen , Koeppen Hartmut , Hsu Jessie J. , Chang Ilsung , Caro Ivor , Rooney Isabelle , McArthur Grant A. , Ribas Antoni
Published: April 2023

Supplementary Table S2 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Supplementary Table S1 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Authors: Yan Yibing , Wongchenko Matthew J. , Robert Caroline , Larkin James , Ascierto Paolo A. , Dréno Brigitte , Maio Michele , Garbe Claus , Chapman Paul B. , Sosman Jeffrey A. , Shi Zhen , Koeppen Hartmut , Hsu Jessie J. , Chang Ilsung , Caro Ivor , Rooney Isabelle , McArthur Grant A. , Ribas Antoni
Published: April 2023

Supplementary Table S1 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Supplementary Methods from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Authors: Bahcall Magda , Awad Mark M. , Sholl Lynette M. , Wilson Frederick H. , Xu Man , Wang Stephen , Palakurthi Sangeetha , Choi Jihyun , Ivanova Elena V. , Leonardi Giulia C. , Ulrich Bryan C. , Paweletz Cloud P. , Kirschmeier Paul T. , Watanabe Masayuki , Baba Hideo , Nishino Mizuki , Nagy Rebecca J. , Lanman Richard B. , Capelletti Marzia , Chambers Emily S. , Redig Amanda J. , VanderLaan Paul A. , Costa Daniel B. , Imamura Yu , Jänne Pasi A.
Published: April 2023

Detailed description of methodology and reagents
Suppl. Table S2 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Authors: Bahcall Magda , Awad Mark M. , Sholl Lynette M. , Wilson Frederick H. , Xu Man , Wang Stephen , Palakurthi Sangeetha , Choi Jihyun , Ivanova Elena V. , Leonardi Giulia C. , Ulrich Bryan C. , Paweletz Cloud P. , Kirschmeier Paul T. , Watanabe Masayuki , Baba Hideo , Nishino Mizuki , Nagy Rebecca J. , Lanman Richard B. , Capelletti Marzia , Chambers Emily S. , Redig Amanda J. , VanderLaan Paul A. , Costa Daniel B. , Imamura Yu , Jänne Pasi A.
Published: April 2023

DFCI358 PDX pharmacodynamics (PD) study design
Suppl. Figure S3 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Authors: Bahcall Magda , Awad Mark M. , Sholl Lynette M. , Wilson Frederick H. , Xu Man , Wang Stephen , Palakurthi Sangeetha , Choi Jihyun , Ivanova Elena V. , Leonardi Giulia C. , Ulrich Bryan C. , Paweletz Cloud P. , Kirschmeier Paul T. , Watanabe Masayuki , Baba Hideo , Nishino Mizuki , Nagy Rebecca J. , Lanman Richard B. , Capelletti Marzia , Chambers Emily S. , Redig Amanda J. , VanderLaan Paul A. , Costa Daniel B. , Imamura Yu , Jänne Pasi A.
Published: April 2023

DFCI358 signaling with respect to mTOR; crizotinib+trametinib combination;RTK activation
Suppl. Figure S1 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Authors: Bahcall Magda , Awad Mark M. , Sholl Lynette M. , Wilson Frederick H. , Xu Man , Wang Stephen , Palakurthi Sangeetha , Choi Jihyun , Ivanova Elena V. , Leonardi Giulia C. , Ulrich Bryan C. , Paweletz Cloud P. , Kirschmeier Paul T. , Watanabe Masayuki , Baba Hideo , Nishino Mizuki , Nagy Rebecca J. , Lanman Richard B. , Capelletti Marzia , Chambers Emily S. , Redig Amanda J. , VanderLaan Paul A. , Costa Daniel B. , Imamura Yu , Jänne Pasi A.
Published: April 2023

The crizotinib-resistant NSCLC from Case #1 retains the MET exon 14 skipping mutation in association with persistent MET protein expression but lacks genomic MET amplification.
Supplementary Figure 1 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Authors: de Leeuw Renée , McNair Christopher , Schiewer Matthew J. , Neupane Neermala Poudel , Brand Lucas J. , Augello Michael A. , Li Zhen , Cheng Larry C. , Yoshida Akihiro , Courtney Sean M. , Hazard E. Starr , Hardiman Gary , Hussain Maha H. , Diehl J. Alan , Drake Justin M. , Kelly Wm. Kevin , Knudsen Karen E.
Published: April 2023

LAPC4 CDK4/6 inhibitor resistance
Supplementary Table 2 from Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Authors: Mahalingam Devalingam , Wang Judy S. , Hamilton Erika P. , Sarantopoulos John , Nemunaitis John , Weems Garry , Carter Laura , Hu Xiao , Schreeder Marshall , Wilkins H. Jeffrey
Published: April 2023

Fold induction over Day 1 pre-dose.
Table A1 from Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
Authors: Chahoud Jad , Sui Dawen , Erwin William D. , Gulbis Alison M. , Korbling Martin , Zhang Mingzhi , Ahmed Sairah , Alatrash Gheath , Anderlini Paolo , Ciurea Stefan O. , Oran Betul , Fayad Luis E. , Bassett Roland L. , Jabbour Elias J. , Medeiros L. Jeffrey , Macapinlac Homer A. , Young Ken H. , Khouri Issa F.
Published: April 2023

Patient demographic characteristics and baseline disease characteristics for groups A, B, C, and D
Supplementary Tables from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
Authors: Welti Jonathan , Sharp Adam , Yuan Wei , Dolling David , Nava Rodrigues Daniel , Figueiredo Ines , Gil Veronica , Neeb Antje , Clarke Matthew , Seed George , Crespo Mateus , Sumanasuriya Semini , Ning Jian , Knight Eleanor , Francis Jeffrey C. , Hughes Ashley , Halsey Wendy S. , Paschalis Alec , Mani Ram S. , Raj Ganesh V. , Plymate Stephen R. , Carreira Suzanne , Boysen Gunther , Chinnaiyan Arul M. , Swain Amanda , de Bono Johann S.
Published: April 2023

Supplementary Tables 1 to 10 Supplementary Table 1: Cell lines ATCC - american type culture collection, FBS - fetal bovine serum, CSS - charcoal stripped serum, * - LNCaP95 cells were kindly provided by Drs. Alan K Meeker and Jun Luo (Johns Hopkins University, Baltimore, Maryland, USA), NA - non-applicable, ^ - phenol red free, BPE/EGF - bovine pituitary extract and human recombinant epidermal growth factor. Supplementary Table 2: ON-TARGETplus siRNA pools for gene expression knock down Supplementary Table 3: TaqMan probes for qRT-PCR analysis Supplementary Table 4: Primary antibodies for western blot analysis Supplementary Table 5: AR regulated genes included in AR activity score Supplementary Table 6: Patient baseline characteristics at prostate cancer diagnosis N - number, SD - standard deviation, IQR - interquartile range, NR - not recorded, PSA - prostate specific antigen, NA - non-applicable. ^5 patient without PSA values; one value >2000 (analyzed as 2000) *All cases adenocarcinoma 1Student's t-test 2Fisher's Exact Test 3Wilcoxon Rank-Sum Test Supplementary Table 7: Cellular pathways regulated by I-BET151 treatment Cellular pathways annotated by CellMap (C), Reactome (R), KEGG (K), NCI PID (N), Panther (P) and BioCarta (B) with p value <0.005 and false discovery rate (FDR) <0.05 are shown. Supplementary Table 8: Alternative splicing events in response to I-BET151 treatment SE - skipped exons, A5SS - alternative 5â€² splice sites, A3SS - alternative 3â€² splice sites, MXE - mutually exclusive exons, RI - retained introns, FDR - false discovery rate, NRCD - normalized reads count difference. All genes with normalized reads count difference (NRCD) >0.2 and <-0.2, and false discovery rate (FDR) <0.05 highlighted in blue. Supplementary Table 9: Patient derived organoids derived from CRPC biopsies harboring AR aberrations. CRPC - castration resistant prostate cancer, AR - androgen receptor, CN - copy number, AR-V7 androgen receptor variant 7, AR-FL - androgen receptor full length, SPOP - substrate-binding adaptor speckle-type POZ protein, IHC - immunohistochemistry H-score. *Mutational, CN analysis or IHC performed on same patient but alternative metastatic biopsy Supplementary Table 10: Patient baseline characteristics at prostate cancer diagnosis. N - number, SE - standard error, NR - not recorded, PSA - prostate specific antigen. *one patient received curative therapy (with oligo-metastatic disease) ^one patient received docetaxel in hormone sensitive setting 1Fisher's Exact Test 2Wilcoxon Rank-Sum Test
Supplementary Methods from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
Authors: Welti Jonathan , Sharp Adam , Yuan Wei , Dolling David , Nava Rodrigues Daniel , Figueiredo Ines , Gil Veronica , Neeb Antje , Clarke Matthew , Seed George , Crespo Mateus , Sumanasuriya Semini , Ning Jian , Knight Eleanor , Francis Jeffrey C. , Hughes Ashley , Halsey Wendy S. , Paschalis Alec , Mani Ram S. , Raj Ganesh V. , Plymate Stephen R. , Carreira Suzanne , Boysen Gunther , Chinnaiyan Arul M. , Swain Amanda , de Bono Johann S.
Published: April 2023

Supplementary Methods
Supplementary figure legends from Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non–Small Cell Lung Cancer
Authors: Wang Yifan , Li Nan , Jiang Wen , Deng Weiye , Ye Rui , Xu Cai , Qiao Yawei , Sharma Amrish , Zhang Ming , Hung Mien-Chie , Lin Steven H.
Published: April 2023

Supplementary figure legends
Supplementary Table S1 from Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non–Small Cell Lung Cancer
Authors: Wang Yifan , Li Nan , Jiang Wen , Deng Weiye , Ye Rui , Xu Cai , Qiao Yawei , Sharma Amrish , Zhang Ming , Hung Mien-Chie , Lin Steven H.
Published: April 2023

Oligos for pLentiCRISPRv2 construction
Supplementary Figures: Supplementary Figure 1.; Supplementary Figure 2.; Supplementary Tables: Supplementary Table 1.; Supplementary Table 2.; Supplementary Table 3.; Supplementary Table 4. from Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial
Authors: Paoletti Costanza , Schiavon Gaia , Dolce Emily M. , Darga Elizabeth P. , Carr T. Hedley , Geradts Joseph , Hoch Matthias , Klinowska Teresa , Lindemann Justin , Marshall Gayle , Morgan Shethah , Patel Parul , Rowlands Vicky , Sathiyayogan Nitharsan , Aung Kimberly , Hamilton Erika , Patel Manish , Armstrong Anne , Jhaveri Komal , Im Seock-Ah , Iqbal Nadia , Butt Fouziah , Dive Caroline , Harrington Elizabeth A. , Barrett J. Carl , Baird Richard , Hayes Daniel F.
Published: April 2023

Supplementary Figures: Supplementary Figure 1. Summary of duration on AZD9496 therapy, previous therapies, and circulating biomarkers status at baseline for each patient ranked by ascending dose; Supplementary Figure 2. Tumor pharmacodynamics. Supplementary Tables: Supplementary Table 1. Study Plan showing time-points of collection of biosamples for exploratory research; Supplementary Table 2. ddPCR primers and probes;Supplementary Table 3. Antibodies and conditions for IHC analysis Antibodies for IHC analysis; Supplementary Table 4. Patients with {greater than or equal to}1 CTC/7.5 mL WB within 120 days of fulvestrant wash-out period prior C1D1.
Supplementary Table 1 from Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population
Authors: Blyuss Oleg , Burnell Matthew , Ryan Andy , Gentry-Maharaj Aleksandra , Mariño Inés P. , Kalsi Jatinderpal , Manchanda Ranjit , Timms John F. , Parmar Mahesh , Skates Steven J. , Jacobs Ian , Zaikin Alexey , Menon Usha
Published: April 2023

MMT / PEB values in training and validation of the algorithms based on the primary analysis
Supplementary Figures from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening
Authors: Beshiri Michael L. , Tice Caitlin M. , Tran Crystal , Nguyen Holly M. , Sowalsky Adam G. , Agarwal Supreet , Jansson Keith H. , Yang Qi , McGowen Kerry M. , Yin JuanJuan , Alilin Aian Neil , Karzai Fatima H. , Dahut William L. , Corey Eva , Kelly Kathleen
Published: April 2023

Supplementary Figures
Tables S1-S5 from Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death
Authors: Lu Haijiao , Zhang Shengzhe , Wu Jie , Chen Minjiang , Cai Mei-Chun , Fu Yujie , Li Wenfeng , Wang Jing , Zhao Xiaojing , Yu Zhuang , Ma Pengfei , Zhuang Guanglei
Published: April 2023

Tables S1-S4 shows details of patient information and Table S5 shows the sgRNA information.
Figure S1 from Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab
Authors: Raja Rajiv , Kuziora Michael , Brohawn Philip Z. , Higgs Brandon W. , Gupta Ashok , Dennis Phillip A. , Ranade Koustubh
Published: April 2023

Correlation between A) mean VAF and B) dVAF calculations from replicate samples obtained from the same patient at screening and pre-dose.
Figure S6 from Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death
Authors: Lu Haijiao , Zhang Shengzhe , Wu Jie , Chen Minjiang , Cai Mei-Chun , Fu Yujie , Li Wenfeng , Wang Jing , Zhao Xiaojing , Yu Zhuang , Ma Pengfei , Zhuang Guanglei
Published: April 2023

A. Cell morphology of inhibitor-treated NCI-H2009, HCC4006 and HCC827 cells with or without DFNA5 overexpression. Red arrows indicated pyroptotic cells. B. LDH release in trametinib-treated A549 cells with genetic depletion of indicated apoptotic genes.
Figure S5 from Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death
Authors: Lu Haijiao , Zhang Shengzhe , Wu Jie , Chen Minjiang , Cai Mei-Chun , Fu Yujie , Li Wenfeng , Wang Jing , Zhao Xiaojing , Yu Zhuang , Ma Pengfei , Zhuang Guanglei
Published: April 2023

A. Cell morphology of inhibitor-treated A549, PC9 and NCI-H3122 cells with or without DFNA5 or CASP3 deletion. Red arrows indicated pyroptotic cells. B. LDH release in A549, PC9 and NCI-H3122 cells treated with indicated inhibitors (zVAD, zDEVD: 100 μM). C. GSDME cleavage and cell morphology of A549, PC9 and NCI-H3122 cells treated with indicated inhibitors. Red arrows indicated pyroptotic cells.
Table S3 from A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers
Authors: Zhu Haiyan , Gu Xiang , Xia Lu , Zhou You , Bouamar Hakim , Yang Junhua , Ding Xiaofei , Zwieb Christian , Zhang Jianan , Hinck Andrew P. , Sun Lu-Zhe , Zhu Xueqiong
Published: April 2023

Supplementary Table3. Upstream regulators that were predicted by Ingenuity Pathway Analysis based on the differentially expressed probesets